Kate F. Byth

1.6k citations

20 papers · 1.0k indexed · h-index 15

Co-authors: Stephen Green Andrew P. Thomas Robert W. Wilkinson Janet D. Culshaw Dongpo Cai Geoffrey I. Shapiro Catherine Geh Nicholas Keen
Topics: Microtubule and mitosis dynamics (7 papers)Cancer-related Molecular Pathways (7 papers)Chronic Lymphocytic Leukemia Research (4 papers)
Cited by: Cell Biology Oncology Cancer Research
Journals: Blood Cancer Research Clinical Cancer Research
Partner nations: United States United Kingdom Spain

In The Last Decade

Kate F. Byth

20 papers receiving 998 citations

Peers

Countries citing papers authored by Kate F. Byth

Since Specialization

Citations

This map shows the geographic impact of Kate F. Byth's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kate F. Byth with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kate F. Byth more than expected).

Fields of papers citing papers by Kate F. Byth

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kate F. Byth. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kate F. Byth. The network helps show where Kate F. Byth may publish in the future.

Co-authorship network of co-authors of Kate F. Byth

This figure shows the co-authorship network connecting the top 25 collaborators of Kate F. Byth. A scholar is included among the top collaborators of Kate F. Byth based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kate F. Byth. Kate F. Byth is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The Specific NLRP3 Antagonist IFM-514 Decreases Fibrosis and Inflammation in Experimental Murine Non-Alcoholic Steatohepatitis 2021 ·Frontiers in Molecular Biosciences ·Sandra Torres,Maximilian Joseph Brol,Fernando Magdaleno,Robert Schierwagen,Frank Erhard Uschner,Sabine Klein,Cristina Ortiz,Olaf Tyc,(unknown),(unknown),Damien Bertheloot,Ana Kitanovic,(unknown),Jacob Schrum,William Roush,Luigi Franchi,Kate F. Byth,Eicke Latz,Jonel Trebicka	22
2	Comparative analysis of primary versus relapse/refractory DLBCL identifies shifts in mutation spectrum 2017 ·Oncotarget ·Danielle Greenawalt,Winnie S. Liang,Sakina Saif,Justin Johnson,Petar V. Todorov,Austin Dulak,Daniel Enríquez,Rebecca F. Halperin,Ambar Ahmed,(unknown),John D. Carpten,David W. Craig,J. Carl Barrett,Brian Dougherty,Michael Zinda,Stephen E. Fawell,Jonathan R. Dry,Kate F. Byth	17
3	Pre-clinical pharmacology of AZD3965, a selective inhibitor of MCT1: DLBCL, NHL and Burkitt’s lymphoma anti-tumor activity 2017 ·Oncotarget ·Nicola J. Curtis,Lorraine Mooney,(unknown),Filippos Michopoulos,(unknown),Haihong Zhong,Clare Murray,Armelle Logié,Mitchell Revill,Kate F. Byth,Amanda Benjamin,Mike Firth,Stephen Green,Paul D. Smith,Susan E. Critchlow	121
4	Differential regulation of mTOR signaling determines sensitivity to AKT inhibition in diffuse large B cell lymphoma 2016 ·Oncotarget ·Scott A. Ezell,Suping Wang,Teeru Bihani,Zhongwu Lai,Shaun Grosskurth,Suprawee Tepsuporn,Barry R. Davies,Dennis Huszar,Kate F. Byth	26
5	Discovery of heterocyclic sulfonamides as sphingosine 1-phosphate receptor 1 (S1P1) antagonists 2015 ·Bioorganic & Medicinal Chemistry Letters ·Edward J. Hennessy,Gurmit Grewal,Kate F. Byth,(unknown),Danyang Li,Paul D. Lyne,Vibha Oza,Lucienne Ronco,Michael Rooney,Jamal Saeh,Qibin Su	2
6	Identification and Optimization of Benzimidazole Sulfonamides as Orally Bioavailable Sphingosine 1-Phosphate Receptor 1 Antagonists with in Vivo Activity 2015 ·Journal of Medicinal Chemistry ·Edward J. Hennessy,Vibha Oza,Ammar Adam,Kate F. Byth,Lillian Castriotta,Gurmit Grewal,Geraldine A. Hamilton,(unknown),Paula Lewis,Danyang Li,Paul D. Lyne,Linda Öster,Michael Rooney,Jamal Saeh,Sha Li,Qibin Su,(unknown),Yafeng Xue,Bin Yang	19
7	Towards the next generation of dual Bcl-2/Bcl-xL inhibitors 2014 ·Bioorganic & Medicinal Chemistry Letters ·Jeffrey Varnes,Thomas W. Gero,Shan Huang,R. Bruce Diebold,(unknown),Paul Grover,Mei Su,Prasenjit Mukherjee,Jamal Saeh,Terry Macintyre,(unknown),Keith Dillman,Kate F. Byth,Daniel Russell,Stephanos Ioannidis	14
8	Synergistic induction of apoptosis by combination of BTK and dual mTORC1/2 inhibitors in diffuse large B cell lymphoma 2014 ·Oncotarget ·Scott A. Ezell,Michele Mayo,Teeru Bihani,Suprawee Tepsuporn,Suping Wang,Melissa Passino,Shaun Grosskurth,Michael P. Collins,Julie Parmentier,Corinne Reimer,Kate F. Byth	41
9	A Dual Bcl-2/xL Inhibitor Induces Tumor Cell Apoptosis in a Hematopoietic Xenograft Model 2014 ·Blood ·Ammar Adam,Kate F. Byth,(unknown),Alwin G. Schuller,Corinne Reimer,(unknown),Terry Macintyre,Francoise Powell	4
10	Essential role of TAK1 in regulating mantle cell lymphoma survival 2012 ·Blood ·Daniela Buglio,Sangeetha Palakurthi,Kate F. Byth,Francisco Vega,Dorin Toader,Jamal Saeh,Sattva S. Neelapu,Anas Younes	50
11	Spleen Tyrosine Kinase Inhibitor Fostamatinib Blocks B Cell Receptor Signaling and Reduces Viability of BCR Subtype Diffuse Large B Cell Lymphoma 2012 ·Blood ·Yue Zhang,Julie Parmentier,Zhongwu Lai,Greg O’Connor,Melissa Passino,Francoise Powell,(unknown),Kate F. Byth	2
12	Inhibition of Tak-1 by AZ-Tak1 Impairs NF-κB Activation, Downregulates XIAP and Activates Caspase-9 Inducing Apoptosis In Mantle Cell lymphoma 2010 ·Blood ·Daniela Buglio,(unknown),Francisco Vega,Sattva S. Neelapu,Donald A. Berry,Yuan Ji,Kate F. Byth,Anas Younes	2
13	AZD5438, a potent oral inhibitor of cyclin-dependent kinases 1, 2, and 9, leads to pharmacodynamic changes and potent antitumor effects in human tumor xenografts 2009 ·Molecular Cancer Therapeutics ·Kate F. Byth,Andrew P. Thomas,Gareth Hughes,(unknown),Alexandra McGregor,Catherine Geh,(unknown),(unknown),Mike Walker,Nicholas J. Newcombe,Stephen Green,Jim Growcott,Andy Barker,Robert W. Wilkinson	104
14	Imidazole pyrimidine amides as potent, orally bioavailable cyclin-dependent kinase inhibitors 2008 ·Bioorganic & Medicinal Chemistry Letters ·Clifford D. Jones,David Andrews,Andrew Barker,Kevin Blades,Kate F. Byth,M. Raymond V. Finlay,Catherine Geh,(unknown),(unknown),Mike Walker,Hazel M. Weir	29
15	AZD1152, a Selective Inhibitor of Aurora B Kinase, Inhibits Human Tumor Xenograft Growth by Inducing Apoptosis 2007 ·Clinical Cancer Research ·Robert W. Wilkinson,Rajesh Odedra,Simon P. Heaton,Stephen R. Wedge,Nicholas Keen,Claire Crafter,John R. Foster,Madeleine C. Brady,Alison Bigley,(unknown),Kate F. Byth,Nigel Barrass,Kirsten Mundt,Kevin M. Foote,Nicola M. Heron,Frédéric Jung,Andrew Mortlock,(unknown),Stephen Green	278
16	A phase I pharmacodynamic study of the effects of the cyclin-dependent kinase-inhibitor AZD5438 on cell cycle markers within the buccal mucosa, plucked scalp hairs and peripheral blood mononucleocytes of healthy male volunteers 2006 ·Cancer Chemotherapy and Pharmacology ·D. Ross Camidge,M. N. Pemberton,Jim Growcott,Dereck D. Amakye,David M. Wilson,Helen Swaisland,(unknown),Robert W. Wilkinson,Kate F. Byth,Andrew Hughes	21
17	AZ703, an Imidazo[1,2-a]Pyridine Inhibitor of Cyclin-Dependent Kinases 1 and 2, Induces E2F-1-Dependent Apoptosis Enhanced by Depletion of Cyclin-Dependent Kinase 9 2006 ·Cancer Research ·Dongpo Cai,Kate F. Byth,Geoffrey I. Shapiro	65
18	The cellular phenotype of AZ703, a novel selective imidazo[1,2-a]pyridine cyclin-dependent kinase inhibitor 2006 ·Molecular Cancer Therapeutics ·Kate F. Byth,Catherine Geh,(unknown),(unknown),Andrew P. Thomas	41
19	Imidazo[1,2- a ]pyridines. Part 2 : SAR and optimisation of a potent and selective class of cyclin-dependent kinase inhibitors 2004 ·Bioorganic & Medicinal Chemistry Letters ·Kate F. Byth,Janet D. Culshaw,Stephen Green,(unknown),Andrew P. Thomas	95
20	Imidazo[1,2- b ]pyridazines: a potent and selective class of cyclin-dependent kinase inhibitors 2004 ·Bioorganic & Medicinal Chemistry Letters ·Kate F. Byth,Nicola J. Cooper,Janet D. Culshaw,(unknown),(unknown),Claire A. Minshull,Richard A. Norman,Richard A. Pauptit,Julie A. Tucker,J. Breed,Andrew Pannifer,Siân Rowsell,(unknown),(unknown),Andrew P. Thomas	64

About Kate F. Byth

Kate F. Byth is a scholar working on Cell Biology, Genetics and Oncology, having authored 20 papers that have together received 1.0k indexed citations. Recurring topics across this work include Microtubule and mitosis dynamics (7 papers), Cancer-related Molecular Pathways (7 papers) and Chronic Lymphocytic Leukemia Research (4 papers). The work is most often cited by research in Cell Biology (281 citations), Oncology (400 citations) and Cancer Research (152 citations). Kate F. Byth has collaborated with scholars based in United States, United Kingdom and Spain. Frequent co-authors include Stephen Green, Andrew P. Thomas, Robert W. Wilkinson, Janet D. Culshaw, Dongpo Cai, Geoffrey I. Shapiro, Catherine Geh, Nicholas Keen, Frédéric Jung and Madeleine C. Brady. Their work appears in journals such as Blood, Cancer Research and Clinical Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact